Pancreatic metastases from renal cell carcinoma are uncommon and their prognostic significance is not well defined. In this analysis we evaluated the outcome of patients with pancreatic metastases treated with either targeted therapies or local treatment to the pancreas. Patients with pancreatic metastases from renal cell carcinoma treated between 1993 and 2014 were identified from 11 European centers. Clinical records were retrospectively reviewed. Kaplan-Meier method and log-rank test were used to evaluate progression-free survival and overall survival. Cox's proportional hazard models were used for survival analysis. In total, 276 PM patients were evaluated, including 77 (28%) patients treated by either surgery or radiotherapy to the pancreas, and 256 (93%) who received systemic therapy. Median time from nephrectomy to diagnosis of pancreatic metastases was 91 months (IQR 54-142). Disease control rate after first-line TTs was 84%, with a median progression-free survival of 12 months (95% CI 10-14). Median overall survival was 73 months (95% CI 61-86) with a 5-year OS of 58%. Median OS of patients treated with local treatment was 106 months (95% CI 78-204) with a 5-year overall survival of 75%. On multivariable analysis, nephrectomy (HR 5.31; 95%CI 2.36-11.92; p<0.0001), Memorial Sloan Kettering/International Metastatic RCC Database Consortium prognostic score (HR 1.45, 95% CI 0.94-2.23 for intermediate vs good vs risk; HR 2.76 95%, CI 1.43-5.35 for poor vs good risk p = 0.0099) and pancreatic local treatment (HR 0.48; 95%CI 0.30-0.78 p = 0.0029) were associated with overall survival. Difference in median OS between patients with PM and that reported in a matched-control group of mRCC patients with extrapancreatic metastases was statistically significant (p <.0001). Pancreatic metastases from renal cell carcinoma usually occur years after nephrectomy, are associated with an indolent behavior and a prolonged survival. Targeted therapies and locoregional approaches are active and achieve high disease control rate.
Clinical impact of Pancreatic metastases from renal cell carcinoma : A multicenter retrospective analysis / P. Grassi, L. Doucet, P. Giglione, V. Grünwald, B. Melichar, L. Galli, U. De Giorgi, R. Sabbatini, C. Ortega, M. Santoni, A. Bamias, E. Verzoni, L. Derosa, H. Studentova, M. Pacifici, J. Coppa, V. Mazzaferro, F. De Braud, C. Porta, B. Escudier, G. Procopio. - In: PLOS ONE. - ISSN 1932-6203. - 11:4(2016 Apr).
|Titolo:||Clinical impact of Pancreatic metastases from renal cell carcinoma : A multicenter retrospective analysis|
|Parole Chiave:||carcinoma, renal cell; combined modality therapy; female; humans; kidney neoplasms; male; middle aged; molecular targeted therapy; neoplasm grading; nephrectomy; pancreatic neoplasms; prognosis; retrospective studies; survival rate; agricultural and biological sciences (all); biochemistry, genetics and molecular biology (all); medicine (all)|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||apr-2016|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1371/journal.pone.0151662|
|Appare nelle tipologie:||01 - Articolo su periodico|